BZ-30
BZ-30 is an orally active broad-spectrum SARS-CoV-2 inhibitor. BZ-30 acts on the early stage of the viral life cycle, can partially inhibit the endosomal entry process and reduce viral replication levels. BZ-30 reduces viral load, improves pulmonary pathological conditions, and decreases the lung-to-body weight ratio in hamster models challenged with SARS-CoV-2. BZ-30 can be used for research related to COVID-19.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 3028405-31-1
- 分子式: C14H13F6N3
- 分子量:337.26
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
BZ-30 (0.15-5 μM) reduces viral RNA levels by ≥99% in wild-type SARS-CoV-2-infected Vero E6 cells at the concentration of 5 μM, and exhibits dose-dependent antiviral activity[1].
BZ-30 (24 h) potently inhibits the effective replication of wild-type SARS-CoV-2 in Vero E6 cells, with an IC50 of 0.65 μM[1].
BZ-30 (24 h) acts as a broad-spectrum inhibitor of SARS-CoV-2 variants of concern in Vero E6 cells, with IC50 values ranging from 0.51 μM (Beta variant) to 12.37 μM (Omicron variant)[1].
BZ-30 can partially inhibit the endosomal entry of SARS-CoV-2 pseudovirus; its inhibitory effect is stronger in HEK293-ACE2 cells (up to 75%) compared with the 50% inhibition rate observed in HEK293-ACE2/TMPRSS2 cells[1].
BZ-30 (0-24 h) acts on the early stage of the wild-type SARS-CoV-2 life cycle in Vero E6 cells, and inhibits viral replication when administered within 2 h post-infection[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Syrian Golden Hamsters (female, 6-8 weeks old, intranasally inoculated with 105 PFU of SARS-CoV-2)[1]
-
Dosage:15 mg/kg
-
Administration:i.p.; twice daily; 4 days (starting 8 h post-infection)
-
Result:Reduced viral load by log10 0.44 TCID50 per mg lung, corresponding to a 64% reduction in viral load.
Significantly reduced the lung-to-body weight ratio.
Maintained body weight comparable to the positive control remdesivir.
Lowered the cumulative histopathological lung score from 14 to 3.
Showed minimal alveolar and epithelial cell degeneration, with only occasional peri-vascular and peri-bronchiolar focal inflammatory cell infiltration.
化学情報
-
CAS 番号 3028405-31-1
-
分子量 337.26
-
分子式 C14H13F6N3
-
SMILES
CC1(CCC1)NC2=NC3=C(C(F)(F)F)C=C(C(F)(F)F)C=C3N2
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
BZ-30 関連分類
HY-183185 関連分類
Powered by Bioz